[go: up one dir, main page]

MX2009007242A - Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas. - Google Patents

Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas.

Info

Publication number
MX2009007242A
MX2009007242A MX2009007242A MX2009007242A MX2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A MX 2009007242 A MX2009007242 A MX 2009007242A
Authority
MX
Mexico
Prior art keywords
treatment
compound
substituted
synaptic responses
glutamatergic synaptic
Prior art date
Application number
MX2009007242A
Other languages
English (en)
Inventor
Alexis Cordi
Gary Rogers
Rudolf Mueller
Original Assignee
Cortex Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc filed Critical Cortex Pharma Inc
Publication of MX2009007242A publication Critical patent/MX2009007242A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a la prevención y tratamiento de insuficiencia cerebral, que incluye el mejoramiento del funcionamiento de receptores en sinapsis en redes cerebrales responsables de los comportamientos de orden superior. Estas redes cerebrales están implicadas en las capacidades cognitivas relacionadas con el deterioro de la memoria, como se observa en una gama de demencias, y en los desequilibrios en la actividad neuronal entre diferentes regiones cerebrales, como se sugiere en trastornos tales como la enfermedad de Alzheimer, esquizofrenia y trastornos afectivos. En un aspecto particular, la presente invención se refiere a un compuesto útil para el tratamiento de tales condiciones, y a métodos de uso de este compuesto para tal tratamiento.
MX2009007242A 2007-01-03 2007-12-28 Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas. MX2009007242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87850307P 2007-01-03 2007-01-03
US92143307P 2007-04-02 2007-04-02
PCT/US2007/026416 WO2008085506A1 (en) 2007-01-03 2007-12-28 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses

Publications (1)

Publication Number Publication Date
MX2009007242A true MX2009007242A (es) 2009-09-02

Family

ID=39608956

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009007242A MX2009007242A (es) 2007-01-03 2007-12-28 Compuesto de [1,2,3]-benzotriazinona 3-sustituida para mejorar respuestas sinapticas glutamatergicas.

Country Status (37)

Country Link
US (1) US8173644B2 (es)
EP (1) EP2144506B1 (es)
JP (1) JP5139446B2 (es)
CN (1) CN101616592B (es)
AP (1) AP2502A (es)
AR (1) AR064740A1 (es)
AT (1) ATE527269T1 (es)
AU (1) AU2007342365B2 (es)
BR (1) BRPI0720749A2 (es)
CA (1) CA2674460C (es)
CR (1) CR10906A (es)
CU (1) CU23804B7 (es)
CY (1) CY1112493T1 (es)
DK (1) DK2144506T3 (es)
EA (1) EA017437B1 (es)
EC (1) ECSP099499A (es)
ES (1) ES2374995T3 (es)
GE (1) GEP20125438B (es)
GT (1) GT200900189A (es)
HN (1) HN2009001268A (es)
HR (1) HRP20110970T1 (es)
IL (1) IL199651A (es)
MA (1) MA31160B1 (es)
ME (1) ME00819B (es)
MX (1) MX2009007242A (es)
MY (1) MY154877A (es)
NI (1) NI200900131A (es)
NZ (1) NZ578293A (es)
PL (1) PL2144506T3 (es)
PT (1) PT2144506E (es)
RS (1) RS52108B (es)
SG (1) SG163545A1 (es)
SI (1) SI2144506T1 (es)
SV (1) SV2009003322A (es)
TN (1) TN2009000277A1 (es)
WO (1) WO2008085506A1 (es)
ZA (1) ZA200904826B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
EA200901546A1 (ru) 2007-05-17 2010-04-30 Кортекс Фармасеутикалс, Инк. Дизамещенные амиды для усиления глутаматергических синаптических ответов
CA2702292A1 (en) 2007-08-10 2009-02-19 Rudolf Mueller Bicyclic amides for ehancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110257186A1 (en) * 2010-04-15 2011-10-20 Staubli Ursula V Compositions and methods for treating visual disorders
US9242938B2 (en) 2011-11-22 2016-01-26 Beijing Medisan Technology Co., Ltd Glycine reuptake inhibitor and use thereof
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
FR3034019B1 (fr) 2015-03-26 2017-03-17 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un antidepresseur et les compositions pharmaceutiques qui la contiennent
KR20180019234A (ko) 2015-06-26 2018-02-23 다케다 야쿠힌 고교 가부시키가이샤 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체
CN106226509B (zh) * 2016-08-12 2019-09-06 中国人民解放军第四军医大学 一种在小鼠前扣带回皮层诱发dse现象的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3723436A (en) * 1971-02-25 1973-03-27 Sun Oil Co Process for aromatic lactams
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
FR2597103B1 (fr) * 1986-04-15 1988-12-16 Provesan Sa Procede de preparation de derives d'oxazinobenzothiazine 6,6-dioxyde
CA2450801C (en) * 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
EP0709384B1 (de) * 1994-10-31 1998-12-23 MERCK PATENT GmbH Benzylpiperidinderivate mit hoher Affinität zu Bindungsstellen von Aminosäure-Rezeptoren
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
AU4416197A (en) * 1996-09-17 1998-04-14 Regents Of The University Of California, The Positive ampa receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US5985871A (en) 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
IL137720A0 (en) 1998-02-18 2001-10-31 Neurosearch As Compounds and their use as positive ampa receptor modulators
US6713474B2 (en) * 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6303542B1 (en) * 2000-08-18 2001-10-16 Rohm And Haas Company Herbicidal 3-substituted-phenyl-1,2,3-benzotriazin-4-ones
CZ2004632A3 (cs) * 2001-11-26 2004-08-18 Cortexápharmaceuticalsźáinc Karbonylbenzoxazinové sloučeniny pro zvýšení glutamátergních synaptických odpovědí
JP2003238555A (ja) * 2002-02-20 2003-08-27 Sumitomo Pharmaceut Co Ltd 細胞死抑制剤
AUPS255202A0 (en) * 2002-05-27 2002-06-13 Monash University Agents and methods for the treatment of disorders associated with motor neuron degeneration
WO2004062616A2 (en) * 2003-01-13 2004-07-29 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
GB0317482D0 (en) * 2003-07-25 2003-08-27 Pfizer Ltd Nicotinamide derivatives useful as pde4 inhibitors
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2007342364A1 (en) * 2007-01-03 2008-07-17 Cortex Pharmaceuticals, Inc. 3-substituted-[1,2,3]benzotriazinone compounds for enhancing glutamatergic synaptic responses
EA200901546A1 (ru) 2007-05-17 2010-04-30 Кортекс Фармасеутикалс, Инк. Дизамещенные амиды для усиления глутаматергических синаптических ответов
CA2702292A1 (en) 2007-08-10 2009-02-19 Rudolf Mueller Bicyclic amides for ehancing glutamatergic synaptic responses
BRPI0815957A2 (pt) 2007-09-20 2019-09-24 Cortex Pharma Inc "composto, composição farmacêutica, métodos e respectivo uso de 1,2,3-triazin-4-onas trissubstituídas e 1,3-pirimidinonas trissubstituídas para a melhora das respostas sinápticas glutamatérgicas"

Also Published As

Publication number Publication date
EA017437B1 (ru) 2012-12-28
ATE527269T1 (de) 2011-10-15
PT2144506E (pt) 2011-12-21
SG163545A1 (en) 2010-08-30
ZA200904826B (en) 2010-09-29
EP2144506B1 (en) 2011-10-05
CU20090117A7 (es) 2011-10-05
US20100137295A1 (en) 2010-06-03
AU2007342365B2 (en) 2012-11-15
IL199651A0 (en) 2010-04-15
GT200900189A (es) 2011-08-02
MA31160B1 (fr) 2010-02-01
WO2008085506A1 (en) 2008-07-17
ES2374995T3 (es) 2012-02-23
CY1112493T1 (el) 2015-12-09
RS52108B (sr) 2012-08-31
AP2009004931A0 (en) 2009-08-31
PL2144506T3 (pl) 2012-04-30
ECSP099499A (es) 2009-10-30
SV2009003322A (es) 2010-02-05
GEP20125438B (en) 2012-03-26
IL199651A (en) 2015-08-31
DK2144506T3 (da) 2012-03-05
EP2144506A1 (en) 2010-01-20
BRPI0720749A2 (pt) 2014-01-14
CA2674460C (en) 2014-07-15
EA200900925A1 (ru) 2009-12-30
HK1140105A1 (en) 2010-10-08
AR064740A1 (es) 2009-04-22
JP2010514838A (ja) 2010-05-06
EP2144506A4 (en) 2010-05-05
JP5139446B2 (ja) 2013-02-06
CR10906A (es) 2009-10-23
AP2502A (en) 2012-10-23
AU2007342365A1 (en) 2008-07-17
CU23804B7 (es) 2012-03-15
ME00819B (me) 2012-03-20
CN101616592A (zh) 2009-12-30
CN101616592B (zh) 2013-06-05
SI2144506T1 (sl) 2012-01-31
MY154877A (en) 2015-08-14
US8173644B2 (en) 2012-05-08
NZ578293A (en) 2012-01-12
CA2674460A1 (en) 2008-07-17
HRP20110970T1 (hr) 2012-01-31
NI200900131A (es) 2010-03-11
HN2009001268A (es) 2011-12-27
TN2009000277A1 (en) 2010-10-18

Similar Documents

Publication Publication Date Title
TN2009000278A1 (en) 3-substituted-[1,2,3] benzotriazinone compounds for enhancing glutamatergic synaptic responses
SG163545A1 (en) 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
BRPI0817271A2 (pt) Método de tratamento da doença de parkinson e outros distúrbios relacionados
EP2340242A4 (en) COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
GB2463833A (en) Methods and compositions for the treatment of neurological disorders
WO2013025997A3 (en) Brain stimulation methods for treating central sensitivity
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
WO2008050341A3 (en) Novel psychotropic agents having glutamate nmda activity
WO2008148801A8 (en) Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission
WO2013029060A3 (en) Compositions and methods for treating neurodegenerative disease
EP2750606A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL AND NEURODEEGENERATIVE DISEASES, DISORDERS AND RELATED METHODS
JP2009537568A5 (es)
WO2003045315A3 (en) Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
UA93306C2 (ru) Соединение 3-замещенного-[1,2,3]-бензотриазинона для улучшения глутаматергических синаптических реакций
EP2552473A4 (en) METHOD FOR THE TREATMENT OF MORBUS PARKINSON AND OTHER DISORDERS OF DOPAMINERGIC NEURONS OF THE BRAIN
IL196615A0 (en) N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
WO2007034326A3 (en) Imidazole compounds for the treatment of neurological disorders
WO2011015646A3 (en) Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
MX2011008060A (es) Derivados de amida biciclica para mejorar las respuestas sinapticas glutamatergicas.
HK1140209A1 (en) Receptor modulators exhibiting neuroprotective and memory enhancing activities
HK1140209B (en) Receptor modulators exhibiting neuroprotective and memory enhancing activities
TN2011000105A1 (en) Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use
HK1173654A1 (zh) 治疗化合物及相关的使用方法

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights